Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging
NCT04752137Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2022
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in Benign neoplasm and malignant neoplasm, sponsored by Massachusetts General Hospital. Primary endpoint: Image-guided prediction of local recurrence at 2 years. Started May 2022; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
Benign neoplasmmalignant neoplasm
Beyond the preview
Go deeper on NCT04752137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752137.